ArticleFrontiers in oncology2025
Cell-in-cell associated lncRNA signature predicts prognosis and immunotherapy response in gastric cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gastric cancer (GC) remains a leading cause of cancer mortality, necessitating robust prognostic biomarkers and personalized therapeutic strategies. Materials and methods: We developed a risk model integrating three cell-in-cell-associated lncRNAs (CICRlncRNAs: AP003392.1, AP000695.2, AL161785.1) using transcriptomic data from 367 TCGA-GC patients. The cohort was randomly split into training (n = 184) and test sets (n = 183) for model construction and external validation. Statistical rigor included LASSO-Cox regression, Kaplan-Meier analysis, and ROC curves assessing 1/3/5-year AUC. Results: The model stratified patients into low- and high-risk groups with distinct overall survival (OS, HR = 2.62, Conclusion: This study establishes CICRlncRNAs as prognostic biomarkers and provides insights for precision therapy, though clinical applicability requires prospective validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.